Mohamed S. Nafie

ATP is not always pro-inflammatory: rethinking purinergic signalling in cancer and autoimmunity

Thieno[2,3-d]pyrimidine scaffold optimization for synergistic c-Met/STAT3 blockade: Synthesis, structure-activity relationships, in vitro potency, and apoptotic pathways in colorectal cancer.

Compounds 17d and 17e were found to be the most potent and exhibited significant anticancer activity across a wide range of cancer cell lines within the NCI-60 panel and are promising leads for further development of dual c-Met/STAT3 inhibitors for treating colorectal cancer.

Mutant isocitrate dehydrogenase in cancer: Structural biology, small-molecule inhibitors, and future drug discovery strategies.

Isocitrate dehydrogenase (IDH) enzymes convert isocitrate to α-ketoglutarate. When IDH1 or IDH2 is mutated, the enzyme gains a new function, and the oncometabolite D-2-hydroxyglutarate (D-2-HG) accumulates. Its epigenetic and metabolic effects depend on the tumor context. This review classifies mutant IDH inhibitors by...

Structure‐Based Design, Synthesis, and Biological Evaluation of Oxadiazole–Morpholine Hybrids as Potent PARP‐1 Inhibitors Inducing Apoptosis in Breast Cancer Cells

Poly(ADP‐ribose) polymerase‐1 (PARP‐1) plays a central role in the repair of DNA single‐strand breaks and represents an established therapeutic target in cancer treatment. In this study, a series of novel oxadiazole–morpholine hybrid compounds was designed and synthesized using a structure‐based drug design approach to...

Discovery of chromone-derived EGFR inhibitors as potent apoptosis inducers in cancer: In vitro and in vivo insights.

Compound 4v emerged as a leading candidate, showing EGFR kinase inhibitory activity comparable to Erlotinib, and computational analysis of 4v and EGFR molecular binding suggests that it serves as a superior binder to the inactive EGFR conformation.